Cardiovascular Diseases Research federal funding in FY2024

Cardiovascular Diseases Research tagged to fiscal year 2024

CARDIOVASCULAR DISEASES RESEARCH and fiscal year 2024 meet in one cell. $20,616,503,227.66 is the obligation sum. 8,652 awards underlie it. A thick research file of thousands of FY rows, not a patient roster. /programs/93.837/ (CFDA 93.837) is the listing without a year filter. /fiscal-years/2024/ (FY2024 federal spending) is the year without a 93.837 filter.

FY2024 holds most of the published 93.837 book. Do not invent NHLBI grantees or hospitals. aging research and allergy research remain other catalog keys. Campaign-finance filings do not fund these USAspending obligations. Correlation with heart-disease mortality headlines is not causation.

Cardiovascular Diseases Research as a catalog title beside FY2024

The official title is CARDIOVASCULAR DISEASES RESEARCH. SpendingVault does not grade clinical-trial phases. $20,616,503,227.66 is a FY2024 obligation sum, not a performance score. Mixing aging research and allergy research into $20,616,503,227.66 would invent a combined total the packet never computed. Program-wide obligations are $24,340,828,120.12 on 11,285 awards.

The FY cell is 84.7% of the program-wide $24,340,828,120.12 book in this extract. Later bulk files can move both the dollars and the 8,652-award count. The All programs index still lists other catalog lines. The FY2024 federal spending hub still lists other FY2024 programs. Neither parent equals this cell.

8,652 FY2024 awards are not a census of labs, trials, or investigators

8,652 is the FY2024 award-record count on CFDA 93.837, not 11,285 program-wide rows treated as labs, trials, or investigators. Continuations and modifications add lines. This page does not publish a typical payment from $20,616,503,227.66 and 8,652. Unique recipients remain unpublished.

What the Cardiovascular Diseases Research FY2024 table omits

No outlays, no named campuses, no trial enrollments, no heart-failure-versus-stroke split. Quote Cardiovascular Diseases Research and FY2024 with $20,616,503,227.66. Keep CFDA 93.837 in the citation. FEC donation tables are a different dataset and do not fund this cell.

Citing Cardiovascular Diseases Research in FY2024

Open /programs/93.837/ for CFDA 93.837, /fiscal-years/2024/ for FY2024 federal spending, /programs/ for All programs, and /ties/ for All spending ties. Those parents are larger than this cell. Keep both join sides on the same line as $20,616,503,227.66. USAspending.gov remains the source.

A ties page exists because two tables meet. One table is CFDA 93.837. The other is fiscal year 2024. $20,616,503,227.66 is the obligation sum on that intersection, not a forecast and not a claim that Cardiovascular Diseases Research caused mortality rates to fall. Step off this pair through the internal links. Keep Cardiovascular Diseases Research and FY2024 together when citing $20,616,503,227.66. CFDA 93.837's program-wide award-record count is 11,285, not a FY2024-only census of labs, trials, or investigators. Obligations of $20,616,503,227.66 are not outlays. Original filings remain on USAspending.gov for this 93.837 × FY2024 pair. Do not add parent hubs into this yearlyTrend cell. Campaign-finance tables do not fund these USAspending obligations. The 84.7% share is $20,616,503,227.66 divided by the program-wide $24,340,828,120.12, not a budget score. Unique recipients remain unpublished on this Cardiovascular Diseases Research FY2024 join. Agency and place-of-performance splits are omitted from this packet. Quote CFDA 93.837, fiscal year 2024, and $20,616,503,227.66 in one sentence. The All programs index and All spending ties index are larger than this cell. A later USAspending ingest can restate $20,616,503,227.66 without changing the join keys. This page is not a heart-disease case or lab census. 8,652 FY2024 award records are not 11,285 program-wide rows. Keep Cardiovascular Diseases Research and FY2024 together when citing $20,616,503,227.66. CFDA 93.837's program-wide award-record count is 11,285, not a FY2024-only census of labs, trials, or investigators.

Questions

How much cardiovascular-disease research was obligated in FY2024?

USAspending.gov records $20,616,503,227.66 in CFDA 93.837 obligations tagged to fiscal year 2024 across 8,652 awards. That cell is 84.7% of the program-wide $24,340,828,120.12 book, not an outlay.

Do 8,652 awards mean 8,652 heart-disease studies?

No. 8,652 is an FY2024 award-record count on a thick research file. The program-wide extract lists 11,285 awards. Recipients are unpublished. USAspending.gov remains the source for this pair. USAspending.gov remains the source for this pair.

Does this include aging research?

No. Aging Research uses CFDA 93.866. Mixing that sibling into $20,616,503,227.66 would invent a combined NIH total the packet never computed. USAspending.gov remains the source for this pair. USAspending.gov remains the source for this pair.

Does $20,616,503,227.66 equal research cash already spent?

No. $20,616,503,227.66 is an obligation aggregate. Outlays are unpublished. FEC donations do not fund this USAspending cell. USAspending.gov remains the source for this pair. USAspending.gov remains the source for this pair. USAspending.gov remains the source for this pair.